注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Fulcrum Therapeutics Inc是一家臨床階段的生物製藥公司。該公司致力於改善基因定義的罕見疾病患者的生活。該公司開發了一種產品引擎,用於識別可調節基因表達的藥物靶點,以治療基因錯誤表達的已知根源疾病。該公司還致力於開發治療肌肉疾病、中樞神經系統疾病和血液疾病的根本原因的藥物。該公司使用其專利產品引擎來識別和驗證藥物靶點,並開發候選產品,以應對某些基因錯誤表達引起的疾病。其候選產品包括losmapimod,它是一種用於治療面肩肱型肌營養不良症(FSHD)的小分子,FTX-6058是一種用於結合胚胎外胚層發育(EED)的小分子。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Kathryn Haviland | 46 | 2018 | Independent Chair of the Board |
Leslie Leinwand | - | - | Member of Scientific Advisory Board |
James J. Collins | 57 | 2017 | Independent Director |
Baziel van Engelen | - | - | Member of FSHD Clinical Advisory Board |
Sonja L. Banks | 54 | 2021 | Independent Director |
H. Lee Sweeney | - | - | Member of Scientific Advisory Board |
Silvere van der Maarel | - | - | Member of FSHD Clinical Advisory Board |
Rabi Tawil | - | - | Member of FSHD Clinical Advisory Board |
Donald E. Ingber | - | 2021 | Member of Scientific Advisory Board |
Jeffrey Statland | - | - | Member of FSHD Clinical Advisory Board |
Patrick Trojer | 50 | 2022 | Member of Scientific Advisory Board |
Robert J. Gould | 68 | 2016 | Director |
James Arthur Geraghty | 68 | 2016 | Independent Director |
Alan Ezekowitz | 69 | 2016 | Independent Director |
Katina Dorton | 65 | 2020 | Independent Director |
Alexander C. Sapir | 57 | 2023 | CEO, President & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核